Evaluation of cytokines for expansion of the megakaryocyte and granulocyte lineages

Stem Cells
J A LaIuppaW M Miller

Abstract

The goal of our study was to identify cytokine combinations that would result in simultaneous ex vivo expansion of both the megakaryocyte (Mk) and granulocyte lineages, since these cell types have the potential to reduce the periods of thrombocytopenia and neutropenia following chemotherapy. We investigated the effects of cytokine combinations on expansion of the Mk (CD41a+ cells and colony forming unit [CFU]-Mk) and granulocyte (CD15+ cells and CFU-granulocyte/monocyte [GM]) lineages. Peripheral blood CD34+ cells were cultured in serum-free medium with interleukin 3 (IL-3), stem cell factor (SCF), and various combinations of thrombopoietin (TPO), IL-6, GM-CSF, and/or G-CSF. The Mk lineage was primarily influenced by TPO in our cultures, although Mk and CFU-Mk numbers were increased when TPO was combined with IL-6. The primary stimulator of the granulocyte lineage was G-CSF, although many synergistic and additive effects were observed with addition of other factors. Expansion of CFU-GM increased upon addition of more cytokines. The cytokine combination of IL-3, SCF, TPO, IL-6, GM-CSF and G-CSF produced the greatest number of granulocytes and CFU-GM. The minimum cytokines necessary for expansion of both the Mk and granulocyte li...Continue Reading

References

Jan 1, 1992·Journal of Hematotherapy·J G BenderL S Schwartzberg
Mar 1, 1992·International Journal of Cell Cloning·H AvrahamJ E Groopman
Feb 1, 1992·Current Opinion in Oncology·R M Stone
Jan 1, 1991·Biomedicine & Pharmacotherapy = Biomédecine & Pharmacothérapie·I BlazsekJ L Misset
Jul 1, 1989·Transfusion Medicine Reviews·D Caussy, D N Sauder
Aug 1, 1989·Proceedings of the National Academy of Sciences of the United States of America·T IshibashiS A Burstein
Jan 1, 1982·Journal of Cellular Physiology. Supplement·H A MessnerC Izaguirre
Oct 1, 1995·Critical Reviews in Oncology/hematology·N Fukushima, H Ohkawa

❮ Previous
Next ❯

Citations

Dec 3, 1999·Clinical and Laboratory Haematology·E M TeggK A Marsden
Jun 9, 2009·Trends in Biotechnology·Nicholas E Timmins, Lars K Nielsen

❮ Previous
Next ❯

Related Concepts

Related Feeds

Allogenic & Autologous Therapies

Allogenic therapies are generated in large batches from unrelated donor tissues such as bone marrow. In contrast, autologous therapies are manufactures as a single lot from the patient being treated. Here is the latest research on allogenic and autologous therapies.